IMbrave050 Study: A Revolutionary Breakthrough in Hepatocellular Carcinoma Adjuvant Therapy
-
Published:2024-02
Issue:
Volume:
Page:101360
-
ISSN:0973-6883
-
Container-title:Journal of Clinical and Experimental Hepatology
-
language:en
-
Short-container-title:Journal of Clinical and Experimental Hepatology
Reference12 articles.
1. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial;Qin;Lancet Lond Engl,2023
2. 2023 Update of Indian National Association for Study of the Liver Consensus on Management of Intermediate and Advanced Hepatocellular Carcinoma: The Puri III Recommendations;Kumar;J Clin Exp Hepatol,2024
3. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma;Finn;N Engl J Med,2020
4. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations;Kumar;J Clin Exp Hepatol,2020
5. Recurrence Patterns and Outcomes after Resection of Hepatocellular Carcinoma within and beyond the Barcelona Clinic Liver Cancer Criteria;Tsilimigras;Ann Surg Oncol,2020